*a) Please cancel claims 60, 65, 81, and 88.*

*b) Please amend the claims as indicated below. For the convenience of the Examiner, a copy of the complete set of pending claims, in the form that they will take after entrance of the present Amendment, is included herewith at the end of Response.*

59. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of an epothilone [macrolide], wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 mg to about 40 mg epothilone per kg body weight.

61. (Amended) The composition of claim 59 [or 60], further comprising at least one additional cytotoxic agent.

63. (Amended) The composition of claim [59] 62, wherein the [anticancer] anti-cancer agent is selected from the group consisting of adriamycin, vinblastin, and paclitaxel.

64. (Amended) A method of treating cancer in a subject comprising:

administering a therapeutically effective amount of an epothilone to a subject in need thereof, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 mg to about 40 mg epothilone per kg body weight.

66. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is [between] an amount sufficient to deliver about 0.01 [mg/kg] to about 40 [mg/kg of] mg epothilone per kg body weight.

67. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is [between] an amount sufficient to deliver about 0.001 [mg/kg] to about 25 [mg/kg of] mg epothilone per kg body weight.

68. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is [between] an amount sufficient to deliver about 0.01 [mg/kg] to about 25 [mg/kg of] mg epothilone per kg body weight.

69. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is [between] an amount sufficient to deliver about 0.001 [mg/kg] to about 10 [mg/kg of] mg epothilone per kg body weight.

70. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is [between] an amount sufficient to deliver about 0.01 [mg/kg] to about 10 [mg/kg of] mg epothilone per kg body weight.

71. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is [between] an amount sufficient to deliver about 0.001 [mg/kg] to about 1 [mg/kg of] mg epothilone per kg body weight.

72. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is [between] an amount sufficient to deliver about 0.01 [mg/kg] to about 1 [mg/kg of] mg epothilone per kg body weight.

73. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 25 [mg/kg] mg or greater [of] epothilone per kg body weight.

74. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is [between] an amount sufficient to deliver about 25 [mg/kg] to about 40 [mg/kg of] mg epothilone per kg body weight.

75. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is effective to kill tumor cells or inhibit the growth of tumor cells.

79. (Amended) The method of claim 64, wherein the therapeutically effective amount of the epothilone is effective to kill multidrug resistant cells or inhibit the growth of multidrug resistant cells.

80. (Amended) A method of treating cancer in a subject comprising administering a therapeutically effective amount of a composition comprising an epothilone, wherein the therapeutically effective amount is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight.

82. (Amended) The method of claim 80, wherein said composition [is administered in combination with] further comprises at least one additional cytotoxic agent.

83. (Amended) The method of claim 82, wherein said at least one additional cytotoxic agent is an anticancer agent.

85. (Amended) A method for treating paclitaxel-resistant cancer comprising:

administering a therapeutically effective amount of an epothilone to a subject in need thereof, [whereby] wherein said therapeutically effective amount of said epothilone is sufficient to kill tumor cells resistant to paclitaxel or inhibit the growth of tumor cells resistant to paclitaxel; and

wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight.

86. (Amended) A method for treating adriamycin-resistant cancer comprising:

administering a therapeutically effective amount of an epothilone to a subject in need thereof, [whereby] wherein said therapeutically effective amount of said epothilone is sufficient to kill tumor cells resistant to adriamycin or inhibit the growth of tumor cells resistant to adriamycin, and

wherein the therapeutically effective amount of the epothilone is an amount sufficient to

deliver about 0.001 to about 40 mg epothilone per kg body weight.

87. (Amended) A method of killing tumor cells or inhibiting the growth of tumor cells comprising:

contacting tumor cells with an amount of a composition comprising an epothilone, effective to kill tumor cells or inhibit the growth of tumor cells, wherein the amount of the epothilone is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight.

89. (Amended) The method of claim 87, wherein said composition is administered in combination with at least one additional cytotoxic agent.

95. (Amended) The method of claim 87, wherein the effective amount of the epothilone is effective to kill multidrug resistant cells or inhibit the growth of multidrug resistant cells.

***II. Addition of Claims***

*Please add the following new claims 96-119:*

--96. A pharmaceutical composition for the treatment of cancer comprising:

a therapeutically effective amount of an epothilone, or pharmaceutically acceptable salts thereof; and

a pharmaceutically acceptable carrier or diluent,

wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight of a subject.

97. The composition of claim 96, further comprising at least one additional cytotoxic agent.

98. The composition of claim 97, wherein said at least one additional cytotoxic agent is an

per kg body weight.

103. The pharmaceutical composition of claim 96, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 to about 10 mg epothilone per kg body weight.

104. The pharmaceutical composition of claim 96, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.01 to about 10 mg epothilone per kg body weight.

105. The pharmaceutical composition of claim 96, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 to about 1 mg epothilone per kg body weight.

106. The pharmaceutical composition of claim 96, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver of about 0.01 to about 1 mg epothilone per kg body weight.

107. A pharmaceutical composition for the treatment of cancer comprising:

a therapeutically effective amount of an epothilone, or pharmaceutically acceptable salts thereof; and

a pharmaceutically acceptable carrier or diluent,

wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.01 mg to about 10 mg epothilone per kg body weight of a subject.

108. A pharmaceutical composition comprising a therapeutically effective amount of an epothilone macrolide, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.01 to about 10 mg epothilone per kg body weight of a subject.

109. A method of treating cancer in a subject comprising:

administering a therapeutically effective amount of an epothilone to a subject in need thereof, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver of about 0.01 to about 10 mg epothilone per kg body weight.

110. A method of treating cancer in a human comprising:

administering a therapeutically effective amount of an epothilone to a subject in need thereof, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.01 to about 10 mg epothilone per kg body weight.

111. The method of claim 64, wherein the step of administering comprises administering multiple times a therapeutically effective amount of an epothilone to a subject in need thereof, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 mg to about 40 mg epothilone per kg body weight.

112. The method of claim 80, wherein the step of administering comprises administering multiple times a therapeutically effective amount of a composition comprising an epothilone, wherein the therapeutically effective amount is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight.

113. The method of claim 64, wherein the step of administering comprises administering multiple times a therapeutically effective amount of an epothilone to a subject in need thereof, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver of about 0.01 to about 10 mg epothilone per kg body weight.

114. The method of claim 80, wherein the step of administering comprises administering multiple times a therapeutically effective amount of a composition comprising an epothilone, wherein the therapeutically effective amount is an amount sufficient to deliver about 0.01 to about 10 mg epothilone per kg body weight.

115. The method of claim 85, wherein the step of administering comprises:

administering multiple times a therapeutically effective amount of an epothilone to a subject in need thereof, wherein said therapeutically effective amount of said epothilone is sufficient to kill tumor cells resistant to paclitaxel or inhibit the growth of tumor cells resistant to paclitaxel; and

wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight.

116. The method of claim 86, wherein the step of administering comprises:

administering multiple times a therapeutically effective amount of an epothilone to a subject in need thereof, wherein said therapeutically effective amount of said epothilone is sufficient to kill tumor cells resistant to adriamycin or inhibit the growth of tumor cells resistant to adriamycin, and

wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight.

117. The method of claim 64, wherein the step of administering comprises:

administering in multiple doses a therapeutically effective amount of an epothilone to a subject in need thereof, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 mg to about 40 mg epothilone per kg body weight.

118. The method of claim 80, wherein the step of administering comprises:

administering in multiple doses a therapeutically effective amount of a composition comprising an epothilone, wherein the therapeutically effective amount is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight.

119. The method of claim 64, wherein the step of administering comprises:

administering in multiple doses a therapeutically effective amount of an epothilone to a subject in need thereof, wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver of about 0.01 to about 10 mg epothilone per kg body weight.

120. The method of claim 80, wherein the step of administering comprises:

administering in multiple doses a therapeutically effective amount of a composition comprising an epothilone, wherein the therapeutically effective amount is an amount sufficient to deliver about 0.01 to about 10 mg epothilone per kg body weight.

121. The method of claim 85, wherein the step of administering comprises:

administering in multiple doses a therapeutically effective amount of an epothilone to a subject in need thereof, wherein said therapeutically effective amount of said epothilone is sufficient to kill tumor cells resistant to paclitaxel or inhibit the growth of tumor cells resistant to paclitaxel; and

wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight.

122. The method of 86, wherein the step of administering comprises:

administering in multiple doses a therapeutically effective amount of an epothilone to a subject in need thereof, wherein said therapeutically effective amount of said epothilone is sufficient to kill tumor cells resistant to adriamycin or inhibit the growth of tumor cells resistant to adriamycin, and

wherein the therapeutically effective amount of the epothilone is an amount sufficient to deliver about 0.001 to about 40 mg epothilone per kg body weight.